Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It develops WVE-120101 and WVE-120102, a stereopure therapeutic candidates, which are in Phase 1b/2a clinical trials for the treatment of Huntington's disease (HD); WVE-003, mutant huntingtin SNP3 program for the treatment of HD; WVE-004, C9orf72 program for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-N531, our Exon 53 program for the treatment of Duchenne muscular dystrophy; and ATXN3 program in SCA3. The company has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, and University of Massachusetts. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
IPO Year: 2015
Exchange: NASDAQ
Website: wavelifesciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/16/2024 | $22.00 | Outperform → Strong Buy | Raymond James |
| 9/27/2024 | $10.00 → $13.00 | Overweight | JP Morgan |
| 9/19/2024 | $11.00 | Buy | B. Riley Securities |
| 9/9/2024 | $10.00 | Overweight | JP Morgan |
| 5/15/2024 | $11.00 | Overweight | Wells Fargo |
| 12/19/2023 | $5.00 → $12.00 | Market Perform → Outperform | Leerink Partners |
| 7/5/2023 | $7.00 | Outperform | Raymond James |
| 5/24/2023 | $7.00 → $5.00 | Buy → Hold | Jefferies |
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4/A - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
CAMBRIDGE, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:30 p.m. GMT / 11:30 a.m. ET. A live webcast of this presentation can be accessed by visiting "Investor Events" on the Investor Relations section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. A replay of this
Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency and announced three wholly owned GalNAc-AIMer preclinical programs that offer first-in-class approaches to address unmet needs in cardiometabolic diseases WVE-007 (INHBE GalNAc-siRNA) clinical trial on track for 1Q 2025; preclinical data demonstrates opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following cessation of GLP-1s Received supportive initial feedback from FDA on WVE-003; FDA is engaged in discussing pathways to accelerated approval and open to Wave's plan to evaluate biomarkers, in
CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, November 12, 2024, to review the company's third quarter 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference
WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q 2025; new preclinical data for WVE-007 demonstrate opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following cessation of GLP-1s Recent proof-of-mechanism data for WVE-006 unlocked Wave's best-in-class RNA editing capabilities; three new wholly owned RNA editing programs targeting PNPLA3, LDLR and APOB are first-in-class approaches to address significant unmet needs in cardiometabolic diseases Wave plans to have five GalNAc-RNA editing or GalNAc-siRNA programs in the clinic by 2026 Wave's clinically validated platform continues to l
Achieved proof-of-mechanism for Wave's RNA editing platform; restoring levels of wild-type (edited) M-AAT that are consistent with the heterozygous "MZ" genotype with low risk of AATD lung and liver disease A single subcutaneous dose of WVE-006 in the first two patients with homozygous "ZZ" AATD resulted in mean plasma total AAT levels of ~11 micromolar, with mean wild-type M-AAT representing more than 60% of total AAT; durable editing with M-AAT protein observed through 57 days Wave expects to share multidose data from the RestorAATion-2 trial in 2025 Annual Research Day on October 30th will highlight WVE-006 proof-of-mechanism data and Wave's new wholly owned GalNAc-RNA editing pr
CAMBRIDGE, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced it will host a virtual Research Day on Wednesday, October 30, 2024 at 10:00 a.m. ET (until 11:30 a.m. ET). During the event, Wave will provide an update on its rapidly advancing, wholly owned pipeline, introduce new GalNAc-conjugated RNA editing and siRNA programs, and discuss its clinically validated discovery and drug development platform, including its novel chemistry innovations enabling best-in-class potency, durability and delivery. The new RNA editing prog
CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today that it closed its previously announced underwritten public offering, and that the underwriters exercised in full their option to purchase an additional 3,750,000 of its ordinary shares at the public offering price of $8.00 per ordinary share, less underwriting discounts and commissions. After giving effect to the full exercise of the underwriters' option to purchase additional shares, the total number of ordinary shares sold in the offering is 26,875,001 ordinary
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Chardan 8th Annual Genetic Medicines Conference in New York City on Tuesday, October 1, 2024, at 1:00 p.m. ET. A live webcast of this presentation will be available on the Investor Relations page of the Wave Life Sciences website at http://ir.wavelifesciences.com. A replay of this presentation will be archived and available on the
CAMBRIDGE, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today the pricing of its previously announced underwritten public offering of 23,125,001 of its ordinary shares at a price to the public of $8.00 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 1,875,023 ordinary shares at an offering price of $7.9999 per pre-funded warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each pre-funded w
CAMBRIDGE, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today that it has commenced an underwritten public offering of $175 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase ordinary shares in an amount up to an additional 15% of the total amount of ordinary shares and shares underlying pre-funded warrants sold in
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)
SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)
SC 13D/A - Wave Life Sciences Ltd. (0001631574) (Subject)
SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)
SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)
SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)
SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)
SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)
SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)
SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)
Raymond James upgraded Wave Life Sciences from Outperform to Strong Buy and set a new price target of $22.00
JP Morgan resumed coverage of Wave Life Sciences with a rating of Overweight and set a new price target of $13.00 from $10.00 previously
B. Riley Securities initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $11.00
JP Morgan initiated coverage of Wave Life Sciences with a rating of Overweight and set a new price target of $10.00
Wells Fargo initiated coverage of Wave Life Sciences with a rating of Overweight and set a new price target of $11.00
Leerink Partners upgraded Wave Life Sciences from Market Perform to Outperform and set a new price target of $12.00 from $5.00 previously
Raymond James initiated coverage of Wave Life Sciences with a rating of Outperform and set a new price target of $7.00
Jefferies downgraded Wave Life Sciences from Buy to Hold and set a new price target of $5.00 from $7.00 previously
SVB Leerink reiterated coverage of WAVE Life Sciences with a rating of Market Perform and set a new price target of $7.00 from $10.00 previously
Mizuho reiterated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $21.00 from $19.00 previously
8-K - Wave Life Sciences Ltd. (0001631574) (Filer)
S-8 - Wave Life Sciences Ltd. (0001631574) (Filer)
S-3ASR - Wave Life Sciences Ltd. (0001631574) (Filer)
8-K - Wave Life Sciences Ltd. (0001631574) (Filer)
8-K - Wave Life Sciences Ltd. (0001631574) (Filer)
8-K - Wave Life Sciences Ltd. (0001631574) (Filer)
8-K - Wave Life Sciences Ltd. (0001631574) (Filer)
424B5 - Wave Life Sciences Ltd. (0001631574) (Filer)
8-K - Wave Life Sciences Ltd. (0001631574) (Filer)
424B5 - Wave Life Sciences Ltd. (0001631574) (Filer)
During the last three months, 4 analysts shared their evaluations of WAVE Life Sciences (NASDAQ:WVE), revealing diverse outlooks from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 0 0 0 2M Ago 0 1 0 0 0 3M Ago 1 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $15.5, a high estimate of $19.00, and a low estimate of $11.00. Observing a dow
HC Wainwright & Co. analyst Andrew Fein reiterates WAVE Life Sciences (NASDAQ:WVE) with a Buy and maintains $15 price target.
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.2% on Wednesday. Shares of Worthington Enterprises, Inc. (NYSE:WOR) fell sharply in today's pre-market trading after the company posted downbeat quarterly results. Worthington Industries posted adjusted earnings of 74 cents per share, missing analysts' estimates of 94 cents per share. The company posted quarterly sales of $318.801 million versus estimates of $359.390 million, according to data from Benzinga Pro. Worthington shares dipped 7.5% to $46.38 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. Taysha Gene Therapies, Inc. (NASDAQ:TS
Mizuho analyst Salim Syed reiterates WAVE Life Sciences (NASDAQ:WVE) with a Outperform and maintains $19 price target.
Wave Life Sciences Ltd (NASDAQ:WVE) announced results from its Phase 1b/2a SELECT-HD trial of WVE-003, which is being developed as a potential disease-modifying therapeutic for Huntington’s disease (HD). WVE-003 is designed to lower mutant huntingtin (mHTT) protein and preserve healthy, wild-type huntingtin (wtHTT) protein. In the multidose portion of the SELECT-HD study (n=23), participants received either every-eight-week (Q8W) intrathecal doses of 30 mg WVE-003 (n=16) or placebo (n=7), with 12 weeks of follow-up. Key results are as follows: WVE-003 was generally safe and well-tolerated, with no Serious Adverse Events (SAEs) reported; ventricular volume was in line with natura
Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation of wild-type huntingtin (wtHTT) protein, and generally safe and well-tolerated profile achieved in 30 mg multidose cohort Statistically significant correlation between mHTT lowering and slowing of caudate atrophy - an imaging biomarker predictive of clinical outcomes Wave to engage regulators on a clinical development path for WVE-003 that would support a potential accelerated approval, and will submit its opt-in package to program partner Takeda Data provide further validation for Wave's RNA medicines platform, including
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on WAVE Life Sciences (NASDAQ:WVE) in the last three months. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 1 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 2 0 1 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $13.4, along with a high estimate of $19.00 and a low estimate of $5.00. This current average reflect
Wells Fargo analyst Tiago Fauth initiates coverage on WAVE Life Sciences (NASDAQ:WVE) with a Overweight rating and announces Price Target of $11.
WAVE Life Sciences (NASDAQ:WVE) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.21) by 14.29 percent. This is a 11.11 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $12.54 million which missed the analyst consensus estimate of $22.95 million by 45.37 percent. This is a 3.02 percent decrease over sales of $12.93 million the same period last year.
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer. Dr. Ingelsson will drive Wave's emerging therapeutic portfolio strategy, including growing its genetics and genomics capabilities for identifying new, high impact targets, and leveraging the company's best-in-class multimodal discovery and development platform to advance transformative RNA medicines. Most recently, Dr. Ingelsson served as Senior Vice President, Head of Target Discovery, at GSK
BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Michael A. Panzara, M.D., MPH to its Board of Directors. Dr. Panzara currently serves as Chief Medical Officer, Head of Therapeutics Discovery and Development at Wave Life Sciences (NASDAQ:WVE) and brings over 20 years of biopharmaceutical industry experience developing therapies for neurological disorders, including in leadership roles at Sanofi Genzyme and Biogen. "Mike is a recognized and experienced leader in the development
CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Jonathan Rosin has been appointed as Chief Human Resources Officer (CHRO). As CHRO, Mr. Rosin will provide strategic enterprise counsel and leadership, both as a member of Wave’s Executive Team and by leading the human resources function. “Jonathan is an accomplished leader with the breadth of human resources experience necessary to help guide Wave as we prepare to support five programs in clinical trials in 2021, as well as advance a robust precl
Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency and announced three wholly owned GalNAc-AIMer preclinical programs that offer first-in-class approaches to address unmet needs in cardiometabolic diseases WVE-007 (INHBE GalNAc-siRNA) clinical trial on track for 1Q 2025; preclinical data demonstrates opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following cessation of GLP-1s Received supportive initial feedback from FDA on WVE-003; FDA is engaged in discussing pathways to accelerated approval and open to Wave's plan to evaluate biomarkers, in
CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, November 12, 2024, to review the company's third quarter 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference
Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high consistency across participants, in a prespecified analysis; dystrophin was comprised of two isoforms consistent with Becker muscular dystrophy patients who display milder disease Data demonstrated meaningful improvement in serum biomarkers for muscle health, with localization of WVE-N531 in myogenic stem cells and regeneration of myofibers Skeletal muscle concentrations of ~41,000 ng/g combined with 61-day tissue half-life support monthly dosing going forward; preclinical data suggest participants may have even higher concentrations in heart and diaphragm WVE-N531 was safe and well tol
Successful clinical translation of Wave's RNA medicines platform in HD patients with WVE-003 provides further validation of Wave's proprietary platform with PN and stereochemistry; opt-in package for WVE-003 submitted to partner Takeda and engagement with regulators initiated to discuss potential path to accelerated approval Dystrophin data on track for 3Q 2024 from potentially registrational FORWARD-53 trial of WVE-N531, which has previously demonstrated industry-leading exon skipping of 53%; positive data would unlock a best-in-class functional dystrophin franchise for DMD Dosing initiated in 3Q 2024 in RestorAATion-2 clinical trial of WVE-006 in AATD patients; proof-of-mechanism da
CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, August 8, 2024, to review the company's second quarter 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference call at the f
Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation of wild-type huntingtin (wtHTT) protein, and generally safe and well-tolerated profile achieved in 30 mg multidose cohort Statistically significant correlation between mHTT lowering and slowing of caudate atrophy - an imaging biomarker predictive of clinical outcomes Wave to engage regulators on a clinical development path for WVE-003 that would support a potential accelerated approval, and will submit its opt-in package to program partner Takeda Data provide further validation for Wave's RNA medicines pla
RestorAATion-2 clinical trial of WVE-006 in AATD patients underway; expected proof-of-mechanism data in patients with AATD remains on track for 2024 INHBE program for obesity expected clinical trial initiation in 1Q 2025; preclinical data demonstrate weight loss similar to semaglutide, fat loss with no loss of muscle mass, and curtailed rebound weight gain upon cessation of semaglutide, with potential for dosing 1 – 2 times per year Continued momentum in GSK collaboration; advancing first two GSK collaboration programs following successful target validation; both programs utilize Wave's GalNAc-siRNA format and discovery collaboration continues to span all Wave modalitie
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 9, 2024, to review the company's first quarter 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference call at the fo
INHBE lead clinical candidate selected; potential best-in-class treatment for obesity with potent and durable silencing, weight loss with no loss of muscle mass, reduction of visceral fat, and every-six-month or annual subcutaneous dosing; clinical trial initiation expected 1Q 2025 Dose escalation ongoing in RestorAATion-1 clinical trial of WVE-006, industry's first-ever RNA editing candidate in the clinic; GalNAc pharmacology translating as expected and proof-of-mechanism data from patients with AATD in RestorAATion-2 on track for 2024 Dystrophin data from potentially registrational FORWARD-53 trial of WVE-N531 in DMD on track for 3Q 2024; industry-leading exon skipping levels, muscl
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, March 6, 2024, to review the company's fourth quarter and full year 2023 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference